Formalization of the whole-part relationship in the unified modeling language

A formal definition for the semantics of the Whole-Part relationship in the Unified Modeling Language or UML is introduced. This provides a fully directly usable specification which that can be incorporated into version 2.0 of UML. An improvement to the current metamodel fragment relating to relationships is proposed, supplemented by the introduction of axioms expressed in the Object Constraint Language or OCL. The overall formalizatlon relates to a clear and concise emphasis on carefully enunciated (primary) characteristics that apply to all instances of a new Whole-Part metatype. Specific kinds of the Whole-Part relationship are defined in terms of secondary characteristics, which must be possessed by subtypes: In UML 1.4, these are Aggregation (a.k.a. white diamond) and Composition (a.k.a. black diamond). Primary and secondary characteristics may then be consistently combined with each other. Consequently, this allows the possible introduction of supplementary forms of Whole-Part. Such a revision is necessary since Aggregation and Composition in UML 1.4 do not cover the full spectrum of Whole-Part theory

Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds —Gastrointestinal Adverse Effects

Background and Aim: Acetylsalicylic acid (ASA [aspirin]) is a commonly used over-the-counter drug for the treatment of pain, fever, or colds, but data on the safety of this use are very limited. The aim of this study was to provide data on the safety of this treatment pattern, which is of interest to clinicians, regulators, and the public. Methods: A meta-analysis of individual patient data from 67 studies sponsored by Bayer HealthCare was completed. The primary endpoints were patient-reported gastrointestinal (GI) adverse events (AEs); the secondary endpoints were the incidence of patient-reported non-GI AEs. Event incidence and odds ratios (ORs) based on Cochran-Mantel-Haenszel estimates are reported. In total, 6181 patients were treated with ASA, 3515 with placebo, 1145 with acetaminophen (paracetamol), and 754 with ibuprofen. Exposure to ASA was short term (82.5% of patients had a single dose). Results: GI AEs were more frequent with ASA (9.9%) than with placebo (9.0%) [OR 1.3; 95% CI 1.1, 1.5]. Dyspeptic symptoms were infrequent (4.6% in placebo subjects). The ORs for ASA were 1.3 (95% CI 1.1, 1.6) versus placebo; 1.55 (95% CI 0.7, 3.3) versus ibuprofen; and 1.04 (95% CI 0.8, 1.4) versus acetaminophen. There were very few serious GI AEs (one ASA case; three placebo cases). No differences were found for non-GI AEs and no cases of cerebral hemorrhage were reported. Conclusion: Short-term, mostly single-dose exposure to ASA for the treatment of pain, fever, or colds was associated with a small but significant increase in the risk of dyspepsia relative to placebo.No serious GI complications were reported